Targeting lung cancer through inhibition of checkpoint kinases

Frontiers in Genetics
Randi G SyljuåsenÅslaug Helland

Abstract

Inhibitors of checkpoint kinases ATR, Chk1, and Wee1 are currently being tested in preclinical and clinical trials. Here, we review the basic principles behind the use of such inhibitors as anticancer agents, and particularly discuss their potential for treatment of lung cancer. As lung cancer is one of the most deadly cancers, new treatment strategies are highly needed. We discuss how checkpoint kinase inhibition in principle can lead to selective killing of lung cancer cells while sparing the surrounding normal tissues. Several features of lung cancer may potentially be exploited for targeting through inhibition of checkpoint kinases, including mutated p53, low ERCC1 levels, amplified Myc, tumor hypoxia and presence of lung cancer stem cells. Synergistic effects have also been reported between inhibitors of ATR/Chk1/Wee1 and conventional lung cancer treatments, such as gemcitabine, cisplatin, or radiation. Altogether, inhibitors of ATR, Chk1, and Wee1 are emerging as new cancer treatment agents, likely to be useful in lung cancer treatment. However, as lung tumors are very diverse, the inhibitors are unlikely to be effective in all patients, and more work is needed to determine how such inhibitors can be utilized in the most ...Continue Reading

References

Oct 27, 1989·Science·T TakahashiJ D Minna
Jun 8, 2001·Molecular and Cellular Biology·H Zhao, H Piwnica-Worms
Feb 28, 2002·Molecular and Cellular Biology·Ester M HammondAmato J Giaccia
Nov 26, 2002·Molecular and Cellular Biology·Timothy P HeffernanWilliam K Kaufmann
Jan 10, 2003·The Journal of Biological Chemistry·Ester M HammondAmato J Giaccia
Mar 12, 2003·Genes & Development·Eric J Brown, David Baltimore
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T YoshidaH Kuwano
Sep 18, 2004·Cancer Research·Ester M HammondAmato J Giaccia
Jan 25, 2005·Nature Cell Biology·Claus Storgaard SørensenThomas Helleday
Apr 15, 2005·Nature·Vassilis G GorgoulisThanos D Halazonetis
Jul 1, 2006·International Journal of Biological Sciences·Yohei TominagaChu-Xia Deng
May 23, 2007·Nature Structural & Molecular Biology·Owen Richard Davies, Luca Pellegrini
Nov 23, 2007·Molecular Biology of the Cell·Benoît FrogetGiuseppe Baldacci
Feb 15, 2008·Nature Reviews. Cancer·Robert G Bristow, Richard P Hill
Mar 8, 2008·Science·Thanos D HalazonetisJiri Bartek
Nov 7, 2008·Nature Reviews. Cancer·Jessica A BertoutM Celeste Simon
Feb 24, 2009·Current Opinion in Cell Biology·Anna M FriedelSusan M Gasser
Mar 12, 2009·Molecular Cancer Research : MCR·Monica RopoloGuido Frosina
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Israel ZighelboimPaul J Goodfellow
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amy M McCordPhilip J Tofilon
Jul 30, 2010·The Journal of Clinical Endocrinology and Metabolism·Henriett ButzAttila Patócs
Aug 19, 2010·Molecular Cancer Therapeutics·Stephen B Keysar, Antonio Jimeno
Sep 30, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Monica OlcinaEster M Hammond
Nov 23, 2010·Trends in Molecular Medicine·Cynthia X MaHelen Piwnica-Worms
Feb 4, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kristina A ColeJohn M Maris
Feb 5, 2011·Biochemical and Biophysical Research Communications·Heekyoung YangHae Yong Yoo
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Esmerina TiliCarlo M Croce

❮ Previous
Next ❯

Citations

Dec 23, 2015·Critical Reviews in Oncology/hematology·Christophe DebenPatrick Pauwels
Sep 20, 2015·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·H Peter Rodemann, Stephan Bodis
Aug 12, 2016·The Lancet Oncology·Wan-Ling TanDaniel S W Tan
Jun 8, 2018·Oncotarget·Aylin CamgozFrank Buchholz
Dec 14, 2018·BMC Bioinformatics·H Robert Frost, Christopher I Amos

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Current Opinion in Pharmacology
Marieke AartsNicholas C Turner
ACS Medicinal Chemistry Letters
Ahmed F Abdel-Magid
Trends in Pharmacological Sciences
Michelle D Garrett, Ian Collins
Experimental and Molecular Pathology
Sarah E Norberto, Sham S Kakar
© 2021 Meta ULC. All rights reserved